October 2, 2016Open Access

Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)

Key Points

Key points are not available for this paper at this time.

Abstract

A novel series of second generation DPP1 inhibitors free from aorta binding liabilities found for earlier compound series was discovered. This work culminated in the identification of compound 30 (AZD7986) as a highly potent, reversible, and selective clinical candidate for COPD, with predicted human PK properties suitable for once daily human dosing.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Doyle et al. (Sun,) studied this question.

synapsesocial.com/papers/69d90b389e924d808f64f521 https://doi.org/https://doi.org/10.1021/acs.jmedchem.6b01127

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate2014 · 54 citations
2Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis2012 · 29 citations
3An Efficient Synthesis of Cyclic β-Amino Acid Derivatives as β-Turn Mimetics2005 · 16 citations
4AZD9668: Pharmacological Characterization of a Novel Oral Inhibitor of Neutrophil Elastase2011 · 121 citations
5Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases2001 · 264 citations

Bookmark

View Full Paper